Physician profile
Robert Belasco
NPI 1972505618
$418.00
in general payments reported to CMS, 2019-2025
10 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2024: $55.36 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $117.73 | 2019 | |
| Pfizer INC. | $66.31 | 2019 | |
| Amgen INC. | $50.58 | 2024-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $49.91 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $29.58 | 2025 | Camzyos, Eliquis |
| Kestra Medical Technology Services, INC. | $27.99 | 2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.13 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $22.54 | 2025 | Verquvo |
| Altathera Pharmaceuticals LLC | $15.35 | 2025 | Sotalol Hydrochloride |
| Inspire Medical Systems, INC. | $13.88 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Belasco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.